Aethlon Medical, Inc., a therapeutic technology company focused on unmet needs in global health and biodefense, reported that the United States Patent and Trademark Office has permitted US Patent Application Number 14/490,418 (“the ‘418 Application”), entitled “Method for removal of viruses from blood by lectin affinity hemodialysis.”
The allowed claims of the ‘418 Application for the Aethlon Hemopurifier embody cartridges by which lectin affinity hemodialysis removes viruses from the blood or plasma of infected patients.
The ‘418 Application is a series of the US Patent Number 7,226,429, which embodies methods for decreasing viral loads in the blood of people infected with a virus.
Together, this intellectual property additionally protects the Aethlon Hemopurifier and secures Aethlon’s position as a leader in pioneering therapeutic strategies to address viral diseases.
The Aethlon Hemopurifier is a first-in-class helpful gadget intended to address hazardous viral infections.
The United States Food and Drug Administration (FDA) has allowed the Hemopurifier as a “Breakthrough Device”. It is related to the treatment of life-threatening viruses that are not addressed to with approved treatments.
Aethlon Medical is intended on addressing unmet needs in global health and biodefense. The Aethlon Hemopurifier is a therapeutic device intended to address life-threatening viral infections.
The United States Food and Drug Administration (FDA) has assigned the Hemopurifier as a Breakthrough Device-related with the treatment of life-threatening viruses.
In collaboration with leading government and non-government research institutes, Aethlon has approved the Hemopurifier to capture a broad-spectrum of pandemic influenza viruses, mosquito-borne viruses, and deadly hemorrhagic viruses.
Based on it, it used to treat Ebola infection; the Hemopurifier was named a “Top 25 Invention” and one of the “Eleven Most Remarkable Advances in Healthcare,” by TIME Magazine.
Aethlon is also examining the potential therapeutic use of the Hemopurifier to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.
Moreover, Aethlon is the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer’s illness (AD) and Chronic Traumatic Encephalopathy (CTE).